Latest Period
Q1 2026
Security Snapshot
CATALYST PHARMACEUTICALS, INC. - Common Stock (CPRX) Institutional Ownership
CUSIP: 14888U101
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
379
Shares (Excl. Options)
104,215,939
Price
$24.76
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CPRX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 104,215,939
- Total 13F value
- $2,579,513,785
- Portfolio coverage rank
- 0%
- Share change
- +192,323
- Value change
- +$7,779,806
- Number of holders
- 379
- Shares outstanding
- 123,180,519
- SEC-reported price per share
- $31.23
- Insider filing price
- $31.23
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CPRX - CATALYST PHARMACEUTICALS, INC. - Common Stock is tracked under CUSIP 14888U101.
- 379 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 374 to 379 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $2,425,290,703 to $2,579,513,785.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 379 institutions filings for Q1 2026.
Security key
14888U101
Latest holder period
Q1 2026
13F holders
379
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
CPRX full holder history
CATALYST PHARMACEUTICALS, INC. SEC filings
CATALYST PHARMACEUTICALS, INC. company facts
CATALYST PHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 14888U101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
CPRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 14% | $399,180,432 | 16,892,951 | BlackRock, Inc. | 31 Mar 2025 | |||
| STATE STREET CORP | 5.2% | $126,186,124 | 6,405,387 | STATE STREET CORPORATION | 30 Sep 2025 | |||
| Flynn James E | 2.6% | $74,033,050 | 3,133,011 | Deerfield Mgmt, L.P. | 31 Dec 2024 |
As of 31 Mar 2026, 379 institutional investors reported holding 104,215,939 shares of CATALYST PHARMACEUTICALS, INC. - Common Stock (CPRX). This represents 85% of the company’s total 123,180,519 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
59%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15% | 18,774,530 | +0.79% | 0.01% | $464,857,361 |
| STATE STREET CORP | 5.6% | 6,863,060 | -0.65% | 0.01% | $169,929,366 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.2% | 5,122,666 | 0% | 0% | $126,837,210 |
| AMERICAN CENTURY COMPANIES INC | 3.4% | 4,138,416 | +37% | 0.05% | $102,467,180 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.2% | 3,943,600 | -20% | 1.2% | $97,643,536 |
| DIMENSIONAL FUND ADVISORS LP | 2.8% | 3,429,615 | +14% | 0.02% | $84,907,655 |
| BANK OF AMERICA CORP /DE/ | 2.5% | 3,036,546 | +38% | 0.01% | $75,184,880 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,972,402 | +2.5% | 0% | $73,609,734 |
| MORGAN STANLEY | 2.2% | 2,687,298 | -8.4% | 0% | $66,537,518 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2% | 2,475,467 | 0% | 0% | $61,292,563 |
| RENAISSANCE TECHNOLOGIES LLC | 1.9% | 2,347,477 | -11% | 0.09% | $58,123,531 |
| ROYCE & ASSOCIATES LP | 1.7% | 2,089,906 | +9.4% | 0.51% | $51,746,073 |
| JANUS HENDERSON GROUP PLC | 1.6% | 1,998,875 | +16% | 0.02% | $49,520,437 |
| Boston Partners | 1.4% | 1,711,573 | +39% | 0.04% | $42,447,185 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.2% | 1,429,842 | +5.4% | 0.01% | $35,402,888 |
| NORTHERN TRUST CORP | 1% | 1,237,752 | +2.1% | 0% | $30,646,739 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.97% | 1,199,598 | -0.83% | 0.63% | $29,702,046 |
| UBS Group AG | 0.8% | 986,090 | +52% | 0% | $24,415,589 |
| GOLDMAN SACHS GROUP INC | 0.8% | 984,734 | +0.53% | 0% | $24,382,014 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.78% | 955,315 | -41% | 0.01% | $23,653,599 |
| RAYMOND JAMES FINANCIAL INC | 0.72% | 889,940 | +5.7% | 0.01% | $21,557,247 |
| VICTORY CAPITAL MANAGEMENT INC | 0.7% | 866,624 | -2% | 0.01% | $21,457,611 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.69% | 852,820 | +419% | 0.03% | $21,115,823 |
| Fundsmith LLP | 0.69% | 844,887 | -75% | 0.16% | $20,919,402 |
| VANGUARD FIDUCIARY TRUST CO | 0.65% | 802,631 | 0% | 0.01% | $19,873,144 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 104,215,939 | $2,579,513,785 | +$7,779,806 | $24.76 | 379 |
| 2025 Q4 | 103,990,575 | $2,425,290,703 | +$6,403,302 | $23.34 | 374 |
| 2025 Q3 | 103,323,297 | $2,035,619,506 | +$33,916,547 | $19.70 | 357 |
| 2025 Q2 | 101,339,025 | $2,199,165,165 | +$74,610,948 | $21.70 | 360 |
| 2025 Q1 | 97,995,812 | $2,374,736,976 | +$45,703,179 | $24.25 | 365 |
| 2024 Q4 | 97,462,582 | $2,034,900,504 | +$38,258,566 | $20.87 | 333 |
| 2024 Q3 | 95,380,838 | $1,896,646,482 | -$35,292,712 | $19.88 | 312 |
| 2024 Q2 | 96,983,113 | $1,502,403,827 | +$11,987,767 | $15.49 | 269 |
| 2024 Q1 | 96,270,213 | $1,534,339,181 | +$191,142,132 | $15.94 | 268 |
| 2023 Q4 | 84,453,649 | $1,419,515,333 | +$62,962,605 | $16.81 | 259 |
| 2023 Q3 | 81,157,485 | $948,788,519 | -$23,397,502 | $11.69 | 254 |
| 2023 Q2 | 82,218,793 | $1,104,943,728 | -$95,298,712 | $13.44 | 243 |
| 2023 Q1 | 88,787,264 | $1,472,124,820 | +$71,196,268 | $16.58 | 256 |
| 2022 Q4 | 84,107,036 | $1,564,456,429 | -$12,268,287 | $18.60 | 252 |
| 2022 Q3 | 85,176,091 | $1,093,105,879 | +$187,635,691 | $12.83 | 220 |
| 2022 Q2 | 75,651,199 | $530,307,280 | +$37,811,777 | $7.01 | 175 |
| 2022 Q1 | 70,838,632 | $586,598,135 | +$41,265,648 | $8.29 | 181 |
| 2021 Q4 | 66,018,446 | $446,683,816 | +$3,690,649 | $6.77 | 160 |
| 2021 Q3 | 65,162,167 | $345,106,769 | -$2,224,745 | $5.30 | 138 |
| 2021 Q2 | 65,482,202 | $376,526,274 | -$10,746,528 | $5.75 | 137 |
| 2021 Q1 | 67,671,701 | $311,885,548 | +$10,809,324 | $4.61 | 130 |
| 2020 Q4 | 66,576,359 | $222,408,153 | -$12,651,094 | $3.34 | 131 |
| 2020 Q3 | 67,907,092 | $201,992,589 | +$603,491 | $2.97 | 140 |
| 2020 Q2 | 64,719,712 | $299,102,386 | -$2,974,113 | $4.62 | 138 |
| 2020 Q1 | 65,840,014 | $253,546,747 | +$11,634,204 | $3.85 | 128 |